von der Maase H - Search Results

1

[Interleukin-2 based immunotherapy of cancer].

Geertsen PF, Hermann GG, Claësson MH, Steven K, Zeuthen J, von der Maase H. Geertsen PF, et al. Among authors: von der maase h. Ugeskr Laeger. 1990 Nov 19;152(47):3513-7. Ugeskr Laeger. 1990. PMID: 2256204 Review. Danish.

2

Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.

Geertsen PF, Hermann GG, von der Maase H, Steven K. Geertsen PF, et al. Among authors: von der maase h. J Clin Oncol. 1992 May;10(5):753-9. doi: 10.1200/JCO.1992.10.5.753. J Clin Oncol. 1992. PMID: 1569448 Clinical Trial.

3

[Urinary bladder cancer].

von der Maase H, Steven K. von der Maase H, et al. Ugeskr Laeger. 2002 Jun 3;164(23):3052-6. Ugeskr Laeger. 2002. PMID: 12082860 Danish. No abstract available.

4

A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium.

Geertsen PF, Sengeløv L, Larsen SK, von der Maase H. Geertsen PF, et al. Among authors: von der maase h. Eur J Cancer. 1993;29A(3):347-50. doi: 10.1016/0959-8049(93)90383-q. Eur J Cancer. 1993. PMID: 8398332 Clinical Trial.

5

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma.

Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Geertsen PF, et al. Among authors: von der maase h. Br J Cancer. 2004 Mar 22;90(6):1156-62. doi: 10.1038/sj.bjc.6601709. Br J Cancer. 2004. PMID: 15026795 Free PMC article. Clinical Trial.

6

[Malignant melanoma of the skin in Denmark--epidemiology, diagnosis and treatment].

von der Maase H, Osterlind A, Drzewiecki KT, Dahlstrøm KK, Geertsen PF, Gjedde SB, Hastrup NC, Holmberg SB, Krag C, Lock-Andersen J, et al. von der Maase H, et al. Ugeskr Laeger. 1992 Jul 6;154(28):1949-53. Ugeskr Laeger. 1992. PMID: 1509557 Review. Danish.

7

Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.

Hermann GG, Geertsen PF, von der Maase H, Steven K, Andersen C, Hald T, Zeuthen J. Hermann GG, et al. Among authors: von der maase h. Cancer Res. 1992 Feb 1;52(3):726-33. Cancer Res. 1992. PMID: 1732060

8

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.

Hermann GG, Geertsen PF, von der Maase H, Zeuthen J. Hermann GG, et al. Among authors: von der maase h. Cancer Immunol Immunother. 1991;34(2):111-4. doi: 10.1007/BF01741344. Cancer Immunol Immunother. 1991. PMID: 1760814 Free PMC article.

9

Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

von der Maase H, Geertsen P, Thatcher N, Jasmin C, Mercatello A, Fosså SD, Symann M, Stoter G, Nagel G, Israel L, et al. von der Maase H, et al. Eur J Cancer. 1991;27(12):1583-9. doi: 10.1016/0277-5379(91)90419-e. Eur J Cancer. 1991. PMID: 1782066 Clinical Trial.

10

Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2.

Geertsen PF, von der Maase H, Olsen NV, Fogh-Andersen N, Nielsen SL, Leyssac PP. Geertsen PF, et al. Among authors: von der maase h. Clin Sci (Lond). 1998 Jul;95(1):73-81. Clin Sci (Lond). 1998. PMID: 9662488 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page